XML Print

Background: Breast cancer is one of the most prevalent malignancies among females. Recognizing specific antigens is highly beneficial for early detection, diagnosis, staging, and prognostic predictions. This study aimed to evaluate the expression and prognostic value of CD56 (140 kDa isoform) in invasive ductal carcinoma (IDC). Methods: In this retrospective study, we included 65 patients with IDC who underwent radical surgery or mastectomy as the primary treatment. Proper formalin-fixed and paraffin embedded tissue blockes of the patients were prepared and stained by immunohistochemistry for CD56 (140 kDa isoform) molecule. Chi-squar and fisher exact tests were used to compare the results against the clinicopathologic data of patients. Kaplan-Meier and log-rank test were employed to study the prognostic value of the target antigen. Results: The pattern of expression of CD56 was granular and cytoplasmic. There was significant associations between the intensity of CD56 expression in invasive cells and carcinoma in situ (P=0.005) and normal ducts (P=0.010).  Among all clinicipathologic parameters, there was only a significant association between the expression of estrogen receptor (ER) and CD56 (P=0.023). Neither overall survival (P=0.356) nor disease-free survival (P=0.976) shared significant associations with CD56 expression. Conclusion: Our data indicate that the CD56 marker offers no prognostic value in terms of predicting the overall survival or disease-free survival for up to 8 years after primary surgery. Furthermore, its expression intensity is similar between normal, non-invasive, and invasive cells. Considering the generally better outcome of ER+ breast cancer patients than their ER- counterparts, the CD56 marker may be indirectly associated with a more favorable prognosis among IDC patients.
Type of Study: Full Length | Subject: Molecular Immunology & Vaccines

Add your comments about this article : Your username or Email:

Send email to the article author

Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

© 2022 CC BY-NC 4.0 | Iranian Biomedical Journal

Designed & Developed by : Yektaweb